OMERS ADMINISTRATION Corp acquired a new stake in shares of LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report) in the 2nd quarter, Holdings Channel reports. The institutional investor acquired 66,100 shares of the company’s stock, valued at approximately $708,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Larson Financial Group LLC increased its stake in LifeStance Health Group by 19,952.6% in the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after acquiring an additional 3,791 shares during the last quarter. KBC Group NV bought a new stake in shares of LifeStance Health Group during the 1st quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its holdings in shares of LifeStance Health Group by 359.1% during the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock worth $44,000 after purchasing an additional 5,404 shares in the last quarter. Bayesian Capital Management LP purchased a new position in shares of LifeStance Health Group during the second quarter worth about $52,000. Finally, PNC Financial Services Group Inc. increased its position in shares of LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the last quarter. 85.50% of the stock is currently owned by hedge funds and other institutional investors.
LifeStance Health Group Trading Up 1.2%
LFST stock opened at $12.30 on Friday. The company has a market capitalization of $4.77 billion, a PE ratio of 94.62 and a beta of 1.14. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. LifeStance Health Group, Inc. has a one year low of $4.77 and a one year high of $12.97. The company’s 50 day moving average price is $11.13 and its two-hundred day moving average price is $8.57.
Insider Buying and Selling at LifeStance Health Group
In other news, CTO Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $481,674.90. Following the transaction, the chief technology officer owned 247,446 shares in the company, valued at approximately $2,684,789.10. The trade was a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $10.85, for a total value of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares of the company’s stock, valued at $3,051,985.65. This represents a 14.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 14,629,850 shares of company stock valued at $154,952,012. Corporate insiders own 3.50% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on LFST shares. Wall Street Zen raised shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 15th. Zacks Research lowered shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. BTIG Research lifted their price objective on shares of LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Weiss Ratings upgraded shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group upped their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $12.38.
Get Our Latest Analysis on LFST
About LifeStance Health Group
LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.
The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.
Featured Stories
- Five stocks we like better than LifeStance Health Group
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Want to see what other hedge funds are holding LFST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LifeStance Health Group, Inc. (NASDAQ:LFST – Free Report).
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
